MedPath

AstraZeneca

AstraZeneca logo
🇬🇧United Kingdom
Ownership
Public
Employees
89.9K
Market Cap
$270.3B
Website
http://www.astrazeneca.co.uk
Introduction

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

PICAROS - Acalabrutinib RWE on 1L CLL in Spain

Active, not recruiting
Conditions
Chronic Lymphocytic Leukemia
First Posted Date
2023-08-21
Last Posted Date
2025-05-06
Lead Sponsor
AstraZeneca
Target Recruit Count
192
Registration Number
NCT05999877
Locations
🇪🇸

Research Site, Murcia, Region De Murcia, Spain

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Phase 3
Recruiting
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
First Posted Date
2023-08-09
Last Posted Date
2025-03-12
Lead Sponsor
AstraZeneca
Target Recruit Count
900
Registration Number
NCT05984277
Locations
🇬🇧

Research Site, Truro, United Kingdom

IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

Phase 4
Withdrawn
Conditions
COPD
Interventions
Drug: Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.
Other: External Comparator
First Posted Date
2023-08-01
Last Posted Date
2024-02-01
Lead Sponsor
AstraZeneca
Registration Number
NCT05970263

A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria

Completed
Conditions
Renal Disease
First Posted Date
2023-08-01
Last Posted Date
2025-04-06
Lead Sponsor
AstraZeneca
Target Recruit Count
2575
Registration Number
NCT05967806
Locations
🇻🇳

Research Site, Ho Chi Minh City, Vietnam

Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population

Phase 1
Completed
Conditions
Hypertension
Interventions
First Posted Date
2023-07-28
Last Posted Date
2023-08-14
Lead Sponsor
AstraZeneca
Target Recruit Count
41
Registration Number
NCT05966324
Locations
🇺🇸

Anaheim Clinical Trials, Anaheim, California, United States

Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

Phase 1
Completed
Conditions
Hypertension
Interventions
First Posted Date
2023-07-27
Last Posted Date
2023-08-14
Lead Sponsor
AstraZeneca
Target Recruit Count
20
Registration Number
NCT05961397
Locations
🇺🇸

American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

🇺🇸

Inland Empire Clinical Trials, Rialto, California, United States

and more 2 locations

Baxdrostat Bioavailability and Bioequivalence Study

Phase 1
Completed
Conditions
Hypertension
Interventions
Drug: baxdrostat (formerly CIN-107) oral solution
First Posted Date
2023-07-27
Last Posted Date
2023-08-14
Lead Sponsor
AstraZeneca
Target Recruit Count
14
Registration Number
NCT05963009
Locations
🇺🇸

Medpace, Cincinnati, Ohio, United States

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

Phase 1
Completed
Conditions
Hypertension
Interventions
First Posted Date
2023-07-27
Last Posted Date
2023-08-15
Lead Sponsor
AstraZeneca
Target Recruit Count
8
Registration Number
NCT05961384
Locations
🇺🇸

Labcorp Clinical Research Unit, Madison, Wisconsin, United States

Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Completed
Conditions
Diffuse Large B Cell Lymphoma
First Posted Date
2023-07-24
Last Posted Date
2025-05-23
Lead Sponsor
AstraZeneca
Target Recruit Count
600
Registration Number
NCT05958134
Locations
🇧🇷

Research Site, Sao Paulo, Brazil

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Placebo
First Posted Date
2023-07-21
Last Posted Date
2023-12-08
Lead Sponsor
AstraZeneca
Target Recruit Count
38
Registration Number
NCT05955183
Locations
🇺🇸

Research Site, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath